Skip to main content
Log in

Overcoming the legal and regulatory barriers to drug repurposing

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Drug repurposing has been proposed as a strategy to develop new therapies that has fewer risks, lower costs and shorter timelines than developing completely new drugs. However, the potential of this strategy has not been as widely realized as hoped, in part owing to legal and regulatory barriers. Here, we highlight these barriers and consider how they could be overcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683 (2004).

    Article  CAS  Google Scholar 

  2. Grabowski, H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat. Rev. Drug Discov. 7, 479–488 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alasdair Breckenridge.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Breckenridge, A., Jacob, R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov 18, 1–2 (2019). https://doi.org/10.1038/nrd.2018.92

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.92

  • Springer Nature Limited

This article is cited by

Navigation